Updated cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma.

Front Oncol · 2024 · PMC11682971 · PMID 39737400

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

The results of the scenario analysis showed that when the model simulated survival time was adjusted to 5 and 20 years, the ICER of the tislelizumab group was 39,811.96 USD/QALY and 31,190.51 USD/QALY, respectively, which shows that there was a decreasing trend in the ICER with the prolongation of the simulated survival time.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.